cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

Author(s):

Ticiana A. Leal, MD,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital

Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.

EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

Now Viewing

EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP: 4.Examining 3-Year Update Data from the CASPIAN Trial

EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP: 12.Examining Key Data from DAREON-8

EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

In patients with LS-SCLC, what would you consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor?
1. Please discuss your thoughts on the range of time prior to initiating therapy - from immediately to 6 weeks post-cCRT.
What is the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC?
1. What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?